
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis</title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis</strong></summary>
            <div>
                <ul><li>- Journal of Hepatology 2017 vol. 67 j 145–172</li></ul>
                
        <details>
            <summary><strong>knowledge test</strong></summary>
            <div>
                <ul><li>- What is the recommended dose for Rifampicin as a second-line therapy for pruritus?</li><li>- In the POISE study, what percentage of patients in the placebo group met the primary endpoint for OCA treatment?</li><li>- What is the 4-year probability of developing esophageal varices in UDCA-treated vs. untreated patients?</li><li>- What is the recommended femur T-score threshold to start osteoporosis treatment?</li><li>- What is the incidence rate of HCC in PBC patients per 1,000 patient-years according to a large multicentre study?</li><li>- What is the average rate of PBC recurrence post-transplant?</li><li>- What is the minimum number of portal fields an adequate liver biopsy should contain?</li><li>- What is the dose-dependent discontinuation rate for OCA due to pruritus?</li><li>- What is the estimated global prevalence of PBC in women over 40?</li><li>- What is the minimum MELD score at which liver transplantation should be considered?</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Introduction to Primary Biliary Cholangitis (PBC)</strong></summary>
            <div>
                <ul><li>- A chronic, progressive, autoimmune cholestatic liver disease predominantly affecting women.</li><li>- Untreated, it can lead to end-stage biliary cirrhosis.</li><li>- Goal of therapy is to prevent disease progression and manage symptoms.</li></ul>
                
        <details>
            <summary><strong>Epidemiology</strong></summary>
            <div>
                <ul><li>- Affects predominantly <u>women</u>.</li><li>- Estimated global prevalence: <q><b>1 in 1,000 women over the age of 40</b></q>.</li><li>- European incidence: <q>1–2 per 100,000 population per year</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Pathogenesis</strong></summary>
            <div>
                <ul><li>- A cycle of immune-mediated biliary epithelial injury, cholestasis, and progressive fibrosis.</li><li>- Involves loss of immunological tolerance to biliary epithelial cells (associated with <b>AMA</b>).</li><li>- Key immune pathways: <b>IL-12</b> and <b>JAK-STAT</b> signalling.</li></ul>
                
        <details>
            <summary><strong>Biliary 'Umbrella' Failure</strong></summary>
            <div>
                <ul><li>- The Cl-/HCO3- exchanger (<b>AE2</b>) and biliary glycocalyx normally protect against hydrophobic bile acids.</li><li>- In PBC, downregulation of <b>AE2</b> sensitizes cholangiocytes to apoptosis, weakening this protective 'umbrella'.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Prognosis without Treatment</strong></summary>
            <div>
                <ul><li>- Historic cohorts showed an average survival of <q><b>9–10 years</b></q> from presentation.</li><li>- <q><u>25%</u></q> of untreated patients developed liver failure during this time.</li><li>- Median time to develop extensive fibrosis is <q><b>2 years</b></q>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Diagnostic Approach to Cholestasis</strong></summary>
            <div>
                <ul><li>- Cholestasis is the impairment of bile formation/flow, considered chronic if it lasts <q>>6 months</q>.</li><li>- Early biochemical markers: Increased serum <b>ALP</b> and <b>GGT</b>.</li></ul>
                
        <details>
            <summary><strong>Initial Evaluation</strong></summary>
            <div>
                <ul><li>- <u>Step 1</u>: Detailed history, physical examination, and abdominal ultrasound.</li><li>- Ultrasound is the first-line imaging to exclude mechanical bile duct obstruction.</li></ul>
                
        <details>
            <summary><strong>Associated Diseases</strong></summary>
            <div>
                <ul><li>- Autoimmune Hashimoto’s thyroiditis</li><li>- Sjögren disease/sicca complex</li><li>- Celiac disease</li><li>- Systemic sclerosis</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Serological Tests</strong></summary>
            <div>
                <ul><li>- <u>Step 2</u>: In chronic intrahepatic cholestasis, test for serum <b>AMA</b> and PBC-specific <b>ANA</b>.</li><li>- AMA is highly sensitive and specific for PBC in the context of unexplained chronic cholestasis.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Extended Imaging</strong></summary>
            <div>
                <ul><li>- <u>Step 3</u>: <b>MRCP</b> is a safe and accurate method for imaging the biliary tree.</li><li>- Essential for diagnosing primary or secondary sclerosing cholangitis.</li><li>- <b>EUS</b> is an alternative for evaluating the distal bile duct.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Liver Biopsy</strong></summary>
            <div>
                <ul><li>- <u>Step 4</u>: Perform if the cause of chronic intrahepatic cholestasis remains unclear after other steps.</li><li>- An adequate biopsy should contain <q><u>at least 11 portal fields</u></q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Genetic Testing</strong></summary>
            <div>
                <ul><li>- Consider for inherited cholestatic syndromes (e.g., PFIC1-3, BRIC) when other diagnoses are ruled out and clinical suspicion is high.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Initial Diagnosis of PBC</strong></summary>
            <div>
                <ul><li>- Suspect PBC in patients with persistent cholestatic liver tests or symptoms like pruritus or fatigue.</li></ul>
                
        <details>
            <summary><strong>Diagnostic Criteria</strong></summary>
            <div>
                <ul><li>- A diagnosis can be made based on:</li><li>- 1. Elevated <b>ALP</b>.</li><li>- 2. Presence of <b>AMA</b> at a titre of <q><b>≥1:40</b></q>.</li><li>- This applies to adult patients with cholestasis and no likelihood of systemic disease.</li></ul>
                
        <details>
            <summary><strong>AMA-Negative PBC</strong></summary>
            <div>
                <ul><li>- Can be diagnosed in patients with cholestasis and specific <b>ANA</b> patterns (nuclear dots or perinuclear rims) or ELISA results for <q><b>sp100</b></q> or <q><b>gp210</b></q>.</li><li>- Occurs in <q>5–10%</q> of PBC patients.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Isolated AMA Positivity</strong></summary>
            <div>
                <ul><li>- <b>AMA reactivity alone is NOT sufficient to diagnose PBC.</b></li><li>- Patients with normal liver tests who are AMA positive should have annual biochemical reassessment.</li><li>- Only <q>one patient out of six</q> with AMA positivity and normal ALP develops PBC within 5 years.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Biochemical & Immunological Markers</strong></summary>
            <div>
                <ul><li>- <b>ALP</b> elevation is typical and associated with disease progression.</li><li>- Increased <b>IgM</b> is a common feature.</li><li>- <b>AST/ALT ratio <q>> 1</q></b> may be a marker of ongoing liver fibrosis.</li><li>- Hyperbilirubinemia is typical of advanced disease.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Role of Liver Biopsy</strong></summary>
            <div>
                <ul><li>- <u>Not necessary for diagnosis</u> if PBC-specific antibodies are present.</li><li>- <b>Essential when</b>:</li><li>- PBC-specific antibodies are absent.</li><li>- Co-existent <b>AIH</b> or <b>NASH</b> is suspected.</li><li>- Other systemic co-morbidities are present.</li></ul>
                
        <details>
            <summary><strong>Histological Features</strong></summary>
            <div>
                <ul><li>- Hallmark: Chronic, non-suppurative inflammation destroying bile ducts, termed '<b>florid duct lesions</b>'.</li><li>- Progressive damage leads to ductopenia and fibrosis.</li><li>- Staging systems (Ludwig, Scheuer, Nakanuma) classify disease from stage 1 to 4 (cirrhosis).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Risk Stratification</strong></summary>
            <div>
                <ul><li>- All patients should be evaluated for their risk of progression to guide therapy.</li><li>- High-risk patients are those with <u>inadequate biochemical response</u> to therapy and/or <u>cirrhosis</u>.</li></ul>
                
        <details>
            <summary><strong>Static Risk Markers (at any time)</strong></summary>
            <div>
                <ul><li>- These markers can be assessed at presentation or during treatment.</li></ul>
                
        <details>
            <summary><strong>Demographics</strong></summary>
            <div>
                <ul><li>- <b>Younger age at diagnosis</b> (e.g., <q><45 years</q>) is a strong risk factor for inadequate response.</li><li>- <b>Male sex</b> is associated with more advanced disease at presentation and poorer response to UDCA.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Serum Tests & Serology</strong></summary>
            <div>
                <ul><li>- Elevated <b>bilirubin</b> and low <b>albumin</b> are markers of advanced disease.</li><li>- Presence of anti-<b>gp210</b>, anti-<b>sp100</b>, and anti-<b>centromere</b> antibodies may predict an unfavorable course.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Liver Stiffness Measurement (LSM)</strong></summary>
            <div>
                <ul><li>- Assessed by Vibration-Controlled Transient Elastography (VCTE).</li><li>- LSM values <q><b>≥9.6 kPa</b></q> are associated with a <q><u>5-fold increased risk</u></q> of liver decompensation, transplant, or death.</li><li>- Worsening LSM over time is a strong predictor of poor outcomes.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Histology</strong></summary>
            <div>
                <ul><li>- Advanced histological stage is associated with poor prognosis.</li><li>- The degree of <b>lymphocytic interface hepatitis</b> is an independent predictor of cirrhosis development.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Dynamic Risk Markers (Response to UDCA)</strong></summary>
            <div>
                <ul><li>- Biochemical response to UDCA, typically assessed after <q><b>12 months</b></q>, is the most validated tool to select patients for second-line therapies.</li></ul>
                
        <details>
            <summary><strong>Qualitative Binary Definitions</strong></summary>
            <div>
                <ul><li>- Simple criteria to define 'responders' vs. 'non-responders'.</li><li>- The <b>Paris-I</b> and <b>Paris-II</b> criteria are widely validated.</li></ul>
                
        <details>
            <summary><strong>Paris-I Criteria</strong></summary>
            <div>
                <ul><li>- Defines inadequate response at 12 months if any of the following are met:</li><li>- <b>ALP</b> <q>≥3 x ULN</q></li><li>- <b>AST</b> <q>≥2 x ULN</q></li><li>- <b>Bilirubin</b> <q>>1 mg/dl</q></li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Paris-II Criteria (for early-stage disease)</strong></summary>
            <div>
                <ul><li>- Defines inadequate response at 12 months if any of the following are met:</li><li>- <b>ALP</b> <q>≥1.5 x ULN</q></li><li>- <b>AST</b> <q>≥1.5 x ULN</q></li><li>- <b>Bilirubin</b> <q>>1 mg/dl</q></li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Toronto Criteria</strong></summary>
            <div>
                <ul><li>- Defines inadequate response at 24 months if:</li><li>- <b>ALP</b> <q>>1.67 x ULN</q></li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Continuous Scoring Systems</strong></summary>
            <div>
                <ul><li>- Incorporate both treatment response and disease severity parameters.</li><li>- <b>GLOBE score</b> and <b>UK-PBC score</b> have shown better performance than binary models.</li><li>- The GLOBE score improves patient classification by nearly <q>10%</q> compared to Paris-I.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Prognosis for Responders</strong></summary>
            <div>
                <ul><li>- Early-stage patients with <b>ALP <q><1.5 x ULN</q></b> and a normal bilirubin after one year of UDCA have a transplant-free survival not significantly different from a healthy population.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Treatment: Therapies to Slow Disease Progression</strong></summary>
            <div>
                <ul><li>- Treatment has been dominated by bile acid-based approaches.</li></ul>
                
        <details>
            <summary><strong>Licensed Therapies</strong></summary>
            <div>
                
                
        <details>
            <summary><strong>Ursodeoxycholic Acid (UDCA)</strong></summary>
            <div>
                <ul><li>- <u>First-line pharmacotherapy for ALL patients with PBC</u>, usually continued for life.</li></ul>
                
        <details>
            <summary><strong>Dose & Mechanism</strong></summary>
            <div>
                <ul><li>- Recommended dose: <q><b>13–15 mg/kg/day</b></q>, can be given as a single daily dose.</li><li>- Mechanism: Acts as a secretagogue, stimulating bile secretion, and has cytoprotective effects.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Efficacy</strong></summary>
            <div>
                <ul><li>- Reduces annual progression rate to extensive fibrosis/cirrhosis (from <q>34%</q> with placebo to <q>7%</q> with UDCA).</li><li>- Reduces 4-year probability of developing esophageal varices (from <q>58%</q> to <q>16%</q>).</li><li>- Combined analysis showed a <q><u>one-third reduction</u></q> in the risk of death or transplant for patients with moderate to severe PBC.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Safety</strong></summary>
            <div>
                <ul><li>- Very safe with minimal side effects (e.g., weight gain, hair thinning).</li><li>- Considered safe to use during pregnancy and breastfeeding.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Obeticholic Acid (OCA)</strong></summary>
            <div>
                <ul><li>- Conditionally approved for patients with an <u>inadequate response to UDCA</u>, or as <u>monotherapy</u> in those intolerant to UDCA.</li></ul>
                
        <details>
            <summary><strong>Dose & Mechanism</strong></summary>
            <div>
                <ul><li>- Initial dose: <q><b>5 mg</b></q> daily.</li><li>- Dose titration to <q><b>10 mg</b></q> daily at six months, according to tolerability.</li><li>- Mechanism: A potent, selective agonist of the <b>farnesoid X receptor (FXR)</b>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Efficacy (POISE Trial)</strong></summary>
            <div>
                <ul><li>- For patients with ALP ≥1.67x ULN and/or elevated bilirubin <2x ULN.</li><li>- Primary endpoint (ALP <1.67x ULN with ≥15% reduction + normal bilirubin) met in:</li><li>- <q><b>47%</b></q> of 10 mg OCA group</li><li>- <q><b>46%</b></q> of 5-10 mg OCA group</li><li>- <q><b>10%</b></q> of placebo group</li><li>- Mean decrease in serum ALP was <q>39%</q> in the 10 mg group vs. <q>5%</q> for placebo.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Side Effects</strong></summary>
            <div>
                <ul><li>- Dose-dependent <b>pruritus</b>, leading to treatment discontinuation in <q><b>1–10%</b></q> of patients.</li><li>- Reversible decrease in HDL cholesterol.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Unlicensed (Off-Label) Therapies</strong></summary>
            <div>
                <ul><li>- Data for these agents are not yet sufficient for a formal recommendation.</li></ul>
                
        <details>
            <summary><strong>Budesonide</strong></summary>
            <div>
                <ul><li>- A synthetic corticosteroid with high first-pass metabolism.</li><li>- Studied as add-on to UDCA in <u>non-cirrhotic</u> patients with interface hepatitis.</li><li>- <b>Caution</b>: Can have deleterious outcomes in patients with cirrhosis and portal hypertension.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Fibric Acid Derivatives (Fibrates)</strong></summary>
            <div>
                <ul><li>- E.g., <b>Bezafibrate</b>, <b>Fenofibrate</b>.</li><li>- Exert anti-cholestatic effects via activation of <b>peroxisome proliferator-activated receptors (PPAR)</b>.</li><li>- Bezafibrate (<q>400 mg/day</q>) as adjunctive therapy showed normalization of ALP in <q>45%</q> of UDCA non-responders.</li><li>- <b>Caution</b>: May cause elevations in ALT/AST and requires monitoring of renal function.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Special Settings & Variants</strong></summary>
            <div>
                
                
        <details>
            <summary><strong>Pregnancy</strong></summary>
            <div>
                <ul><li>- Typically well tolerated in non-cirrhotic patients.</li><li>- <b>UDCA</b> use is recommended to be continued (considered safe).</li><li>- Pruritus management may require specialist advice; <b>Rifampicin</b> has been used by experts during the <q><u>third trimester</u></q>.</li><li>- Patients with cirrhosis have higher risks and require pre-conception counselling and specialist monitoring.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>PBC with Features of Autoimmune Hepatitis (AIH)</strong></summary>
            <div>
                <ul><li>- Occurs in <q><b>~8-10%</b></q> of cases, presenting simultaneously or sequentially.</li><li>- Suspect in patients with disproportionate elevations in <b>ALT</b> and/or <b>IgG</b>.</li></ul>
                
        <details>
            <summary><strong>Diagnosis (Paris Criteria)</strong></summary>
            <div>
                <ul><li>- <u><b>Liver biopsy is mandatory</b></u> for confirmation.</li><li>- Diagnosis requires meeting criteria for both PBC and AIH.</li><li>- <b>AIH features (need ≥2 of 3)</b>:</li><li>- <b>ALT</b> <q>≥5 x ULN</q></li><li>- <b>IgG</b> <q>≥2 x ULN</q> or positive smooth muscle antibody (SMA)</li><li>- Histology: Moderate or severe interface hepatitis</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Treatment</strong></summary>
            <div>
                <ul><li>- Patients may benefit from <b>immunosuppressive treatment</b> in addition to <b>UDCA</b>.</li><li>- Recommended for patients with <u>severe</u> interface hepatitis.</li><li>- Should be considered for patients with <u>moderate</u> interface hepatitis.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Management of Symptoms & Complications</strong></summary>
            <div>
                <ul><li>- Symptom severity does not necessarily correlate with the stage of liver disease.</li></ul>
                
        <details>
            <summary><strong>Pruritus (Itch)</strong></summary>
            <div>
                <ul><li>- A characteristic cholestatic symptom that impairs quality of life.</li><li>- A step-wise therapeutic approach is recommended.</li></ul>
                
        <details>
            <summary><strong>1st Line: Bile Acid Sequestrants</strong></summary>
            <div>
                <ul><li>- <b>Cholestyramine</b> is recommended first-line despite limited evidence, due to its safety profile.</li><li>- <b>Important</b>: Must be given <q><b>2–4 hours</b></q> before or after other medications (including UDCA/OCA) to avoid interfering with their absorption.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>2nd Line: Rifampicin</strong></summary>
            <div>
                <ul><li>- Dose: <q><b>150 mg–300 mg daily</b></q>.</li><li>- Requires monitoring of serum liver tests due to potential hepatotoxicity.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>3rd Line: Opiate Antagonists</strong></summary>
            <div>
                <ul><li>- <b>Naltrexone</b> can reduce the sensation of itching.</li><li>- Start at a low dose to avoid opiate withdrawal-like reactions.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Other Therapies (Empirical)</strong></summary>
            <div>
                <ul><li>- <b>Sertraline</b> (SSRI) and <b>Gabapentin</b> are used empirically for unresponsive pruritus.</li><li>- Evidence is limited to small trials or case reports.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Salvage & Experimental Therapies</strong></summary>
            <div>
                <ul><li>- For extreme, unresponsive pruritus, restricted to specialist centres.</li><li>- Options include:</li><li>- Nasobiliary drainage</li><li>- Molecular Adsorbance Recirculating System (MARS)</li><li>- Ultraviolet (UV) light therapy</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Liver Transplantation</strong></summary>
            <div>
                <ul><li>- Highly effective, with rapid reduction in pruritus severity, often within <q>24 hours</q> post-transplant.</li><li>- An indication for 'persistent and intractable' pruritus refractory to medical therapy.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Fatigue</strong></summary>
            <div>
                <ul><li>- Frequently reported by <q>>50%</q> of patients; severe in <q>20%</q>.</li><li>- Not related to liver disease severity (except in end-stage disease).</li><li>- Not responsive to UDCA or OCA therapy.</li><li>- <b>Transplantation is not an indication for fatigue alone</b>, as it often persists post-transplant.</li></ul>
                
        <details>
            <summary><strong>Management Approach</strong></summary>
            <div>
                <ul><li>- A structured approach is essential.</li><li>- <u>Seek and treat</u> associated/alternate causes: anaemia, hypothyroidism, sleep disturbance.</li><li>- Advise on coping strategies and avoidance of social isolation.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Contributing Factors</strong></summary>
            <div>
                <ul><li>- Pruritus at night</li><li>- Autonomic dysfunction</li><li>- Dehydration</li><li>- Restless legs</li><li>- Concurrent medications (e.g., beta-blockers)</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Sicca Complex (Dry Eyes/Mouth)</strong></summary>
            <div>
                <ul><li>- Common in PBC; most patients have sicca symptoms rather than primary Sjögren’s syndrome.</li></ul>
                
        <details>
            <summary><strong>Treatment</strong></summary>
            <div>
                <ul><li>- <b>Artificial tears and saliva</b> are often helpful.</li><li>- <b>Pilocarpine</b> or <b>cevimeline</b> can be used for refractory symptoms.</li><li>- Advise on oral hygiene to prevent dental caries.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Miscellaneous Manifestations</strong></summary>
            <div>
                <ul><li>- <b>Raynaud’s phenomenon</b>: Occurs in up to <q>one-quarter</q> of patients.</li><li>- <b>Limited scleroderma (CREST syndrome)</b>: Occurs in <q>~8%</q> of patients. Refer for rheumatology advice.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Management of Liver Disease Complications</strong></summary>
            <div>
                
                
        <details>
            <summary><strong>Osteoporosis</strong></summary>
            <div>
                <ul><li>- A common complication in PBC.</li></ul>
                
        <details>
            <summary><strong>Risk Assessment & Monitoring</strong></summary>
            <div>
                <ul><li>- Assess risk in all patients.</li><li>- Use <b>DEXA scan</b> at presentation to assess bone mineral density.</li><li>- Follow-up assessment between <q>1 and 5 years</q> later depending on risk.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Treatment</strong></summary>
            <div>
                <ul><li>- It seems reasonable to treat patients with a femur T-score <q><b>lower than -1.5</b></q>.</li><li>- <b>Bisphosphonates</b> (e.g., alendronate) are effective.</li><li>- <b>Caution</b>: Oral bisphosphonates may cause esophagitis; use with care in patients with esophageal varices. Parenteral forms can be considered.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Supplementation</strong></summary>
            <div>
                <ul><li>- Calcium and Vitamin D supplements can be considered, according to local practice.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Fat-Soluble Vitamin Deficiency</strong></summary>
            <div>
                <ul><li>- Deficiencies in vitamins A, D, E, and K are <u>uncommon</u> in PBC, except in patients with prolonged jaundice.</li><li>- Consider measuring levels and supplementing on an individual basis, particularly if icteric.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Hyperlipidaemia</strong></summary>
            <div>
                <ul><li>- Elevated serum lipids occur in up to <q>80%</q> of patients.</li><li>- Characterized by elevated <b>HDL</b> and presence of anti-atherogenic <b>lipoprotein X</b>.</li><li>- <b>No substantial evidence</b> supports an elevated cardiovascular risk in PBC.</li><li>- Treatment is not routinely indicated unless concomitant classical cardiovascular risk factors are present.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Varices & Portal Hypertension</strong></summary>
            <div>
                <ul><li>- Can develop in pre-cirrhotic stages, but this is rare.</li><li>- <q>95%</q> of patients with varices have other markers of high-risk disease.</li><li>- Management should follow the <b>Baveno-VI guidelines</b>.</li></ul>
                
        <details>
            <summary><strong>Screening Indication</strong></summary>
            <div>
                <ul><li>- Consider screening endoscopy if:</li><li>- LSM <q>≥20 kPa</q></li><li>- Platelet count <q><150 x 10^9 cells/L</q></li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Hepatocellular Carcinoma (HCC)</strong></summary>
            <div>
                <ul><li>- A serious complication of cirrhosis in PBC.</li></ul>
                
        <details>
            <summary><strong>Incidence & Risk Factors</strong></summary>
            <div>
                <ul><li>- Incidence rate: <q><b>3.4 cases per 1,000 patient-years</b></q>.</li><li>- Key risk factors:</li><li>- <b>Male sex</b></li><li>- <b>Inadequate response to UDCA</b></li><li>- <b>Advanced histological stage (cirrhosis)</b></li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Surveillance</strong></summary>
            <div>
                <ul><li>- HCC surveillance according to EASL guidelines is indicated for patients with suspected or confirmed cirrhosis.</li><li>- Typically involves ultrasound +/- alpha fetoprotein every <q>6 months</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Liver Transplantation</strong></summary>
            <div>
                <ul><li>- The prevalence of PBC as an indication for transplant has declined.</li></ul>
                
        <details>
            <summary><strong>Indications for Assessment</strong></summary>
            <div>
                <ul><li>- Complications of cirrhosis (variceal bleed, ascites, encephalopathy).</li><li>- Markers of disease severity:</li><li>- MELD score <q><b>≥15</b></q></li><li>- Progressively rising bilirubin <q><b>>50–85 μmol/L (3–5 mg/dl)</b></q></li><li>- Severe, medically resistant pruritus.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Outcomes</strong></summary>
            <div>
                <ul><li>- Generally favorable, with 5-year patient survival rates of <q><b>80–85%</b></q>.</li><li>- Symptoms like <b>fatigue</b> frequently persist post-transplant.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Recurrence of PBC</strong></summary>
            <div>
                <ul><li>- Reported in <q><b>~20%</b></q> of patients on average, though histological recurrence may be higher.</li><li>- Infrequently leads to graft loss.</li><li>- Use of UDCA post-transplant is safe and can improve liver biochemistry, but evidence for preventing recurrence is insufficient for a strong recommendation.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Organisation of Clinical Care</strong></summary>
            <div>
                <ul><li>- Optimal care requires a structured, life-long, and individualized approach.</li></ul>
                
        <details>
            <summary><strong>Care Pathways</strong></summary>
            <div>
                <ul><li>- All patients should have a structured life-long follow-up.</li><li>- A minimum of an <u>annual assessment</u> of treatment needs and symptom status is recommended.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Clinical Audit Standards</strong></summary>
            <div>
                <ul><li>- Proposed standards to improve quality of care:</li></ul>
                
        <details>
            <summary><strong>Baseline Assessment</strong></summary>
            <div>
                <ul><li>- All patients with suspected PBC should have an abdominal ultrasound (standard <q>90%</q>).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>First-Line Therapy</strong></summary>
            <div>
                <ul><li>- UDCA at <q>13–15 mg/kg/day</q> should be used in all patients (standard <q>90%</q>).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Risk Stratification</strong></summary>
            <div>
                <ul><li>- Document biochemical response after one year of UDCA (standard <q>80%</q>).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Symptom Evaluation</strong></summary>
            <div>
                <ul><li>- Evaluate all patients for pruritus, sicca complex, and fatigue annually (standard <q>90%</q>).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Transplant Referral</strong></summary>
            <div>
                <ul><li>- Discuss patients with bilirubin <q>>50 μmol/l</q> or decompensated disease with a transplant-linked hepatologist (standard <q>90%</q>).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Patient Support</strong></summary>
            <div>
                <ul><li>- Patients should be informed of available support from patient groups.</li><li>- Psychological distress associated with fatigue may warrant referral to psychological services.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
    </div>
    
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
